

## **Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5**

TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that it will host a conference call and webcast on Monday, November 5, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three and nine months ended September 30, 2018.

### ***Conference Call & Webcast:***

#### **Monday, November 5 @ 8:30am Eastern Time**

Within the US:	800-239-9838
Outside the US:	323-794-2551
From Israel:	1809 212 883
Conference ID:	9320949
Webcast:	<a href="http://public.viavid.com/index.php?id=131686">http://public.viavid.com/index.php?id=131686</a>

#### ***Replays, Available through November 19:***

Domestic:	844-512-2921
International:	412-317-6671
Replay PIN:	9320949

### ***About Galmed Pharmaceuticals Ltd.***

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

For further information: Timothy McCarthy, LifeSci Advisors, LLC, +1-212-915-2564,  
tim@lifesciadvisors.com Guy Nehemya, VP Operations, Galmed Pharmaceuticals Ltd.,  
guy@galmedpharma.com

---

Additional assets available online: [Photos \(1\)](#)

<https://galmedpharma.investorroom.com/2018-10-29-Galmed-Pharmaceuticals-to-Report-Third-Quarter-2018-Financial-Results-and-Provide-Business-Update-on-Monday-November-5>